Why Is GRAIL INC EQUITY Equity (GRAL) Stock Down Today?
By the Top Tier Newswire AI Desk · August 6, 2026 at 10:48 AM ET · reviewed against 3 wire stories
GRAIL INC EQUITY Equity (GRAL) is down -12.93% in the latest session. Our newswire has captured 3 stories on GRAL across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why GRAL stock is down today
GRAIL Inc. (GRAL) fell 12.93% to $64.59 in early trading on Monday. The decline came after the company reported its second-quarter 2026 earnings results and filed a Form 8-K with the SEC on August 5, 2026. The earnings call included guidance for an FDA advisory committee meeting in the fall and a potential approval in early 2027.
What Happened
GRAIL reported Q2 2026 results with revenue of $44.7 million, a figure that beat estimates. However, the stock opened with an 8.3% gap down from its prior close of $74.18, reflecting investor reaction to the earnings call and the broader market context. The company’s CEO and CFO participated in the call, where they outlined progress with the Galleri test, including a partnership with Samsung and discussions around regulatory pathways. The stock continued to fall throughout the morning session, hitting a low of $64.25 before stabilizing slightly.
The company also filed a Form 8-K to disclose its financial results and operations, which included a net loss and a negative EPS of -$2.56 for the quarter. While the earnings beat estimates, the broader fundamentals remain challenging, with a trailing twelve-month EPS of -$10.31 and a net margin of -253.2%. The stock has also seen recent insider activity, with the Chief Growth Officer selling shares on June 4.
What The Data Shows
The stock traded at 0.8 times its 3-month average volume, with 500,000 shares changing hands. The session high of $70.45 and low of $64.25 indicate a volatile morning session. Over the last 30 days, sentiment has improved slightly to 43 out of 100, up from an average of 37. The stock currently trades within its 52-week range of $29.95 to $118.84, reflecting a market cap of $3.1 billion.
What To Watch
GRAIL has no upcoming earnings date listed but will need to continue providing updates on its FDA approval timeline and commercial progress. Analysts from Mizuho, Goldman Sachs, and TD Cowen have maintained or initiated coverage with price targets ranging from $60 to $69.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GRAL · Aug 6 session (5-min) · -14.53% vs prior close · updated 8:44 PM ETAI sentiment, last 36h · averaged over 3 stories · 56/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoSeeking AlphaBULLISH 67Product/PR
GRAIL anticipates FDA advisory committee in fall while projecting potential approval in first part of 2027
GRAIL (GRAL) Q2 2026 earnings call recap: Galleri test demand, Samsung partnership, $44.7M revenue, and FDA AdCom timing toward 2027 approval—read now.
4d agoSeeking AlphaNEUTRAL 50Earnings
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsJoshua Ofman - CEO & DirectorAaron Freidin - CFO & Head of...
5d agoSEC 8-KNEUTRAL 50General
GRAIL, Inc. (GRAL) files 8-K
Filed: 2026-08-05 AccNo: 0001628280-26-053341 Size: 363 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →